Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design

BMC Medicine

Volumn 16, Issue 1, 2018, Pages

  Dimairo, Munyaradzi ^a   Coates, Elizabeth ^a   Pallmann, Philip ^b   Todd, Susan ^c   Julious, Steven A ^a   Jaki, Thomas ^d   Wason, James ^e,n   Mander, Adrian P ^e   Weir, Christopher J ^f   Koenig, Franz ^g   Walton, Marc K ^h   Biggs, Katie ^a   Nicholl, Jon ^a   Hamasaki, Toshimitsu ⁱ   Proschan, Michael A ^j   Scott, John A ^k   Ando, Yuki ^l   Hind, Daniel ^a   Altman, Douglas G ^m  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF READING   (United Kingdom)

^d LANCASTER UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁱ NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^l PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^m UNIVERSITY OF OXFORD   (United Kingdom)

ⁿ NEWCASTLE UNIVERSITY   (United Kingdom)

more..

Author keywords

Adaptive design; CONSORT extension; Flexible design; Randomised controlled trial; Reporting guidance; Reporting guideline

Indexed keywords

ARTICLE; ASIA; CHECKLIST; CONTROLLED STUDY; DECISION MAKING; DELPHI STUDY; EUROPE; HUMAN; HUMAN EXPERIMENT; RANDOMIZED CONTROLLED TRIAL; WRITING; CONSENSUS; DECISION SUPPORT SYSTEM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

ASIA; CHECKLIST; CONSENSUS; DECISION SUPPORT TECHNIQUES; EUROPE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 85056664174     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-018-1196-2     Document Type: Article

References (85)

1. Lauer MS, Gordon D, Wei G, Pearson G. Efficient design of clinical trials and epidemiological research: is it possible? Nat Rev Cardiol. 2017;14(8):493-501.
2. O'Neill RT. FDA's critical path initiative: a perspective on contributions of biostatistics. Biom J. 2006;48:559-64.
3. Chow S-C. Adaptive clinical trial design. Annu Rev Med. Annual Reviews. 2014;65:405-15.
4. CHMP. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007.
5. FDA. Guidance for industry: adaptive design clinical trials for drugs and biologics. 2010.
6. FDA. Adaptive designs for medical device clinical studies: draft guidance for industry and Food and Drug Administration staff. 2015.
7. Bauer P, Bretz F, Dragalin V, König F, Wassmer G. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. Stat Med. 2016;35:325-47.
8. Bretz F, Koenig F, Brannath W, Glimm E, Posch M. Adaptive designs for confirmatory clinical trials. Stat Med. 2009;28:1181-217.
9. Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. BioMed Central. 2018;16:29.
10. Guetterman TC, Fetters MD, Legocki LJ, Mawocha S, Barsan WG, Lewis RJ, et al. Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process-findings from a qualitative study. Clin Res Regul Aff. 2015;32:121-30.
11. Rong Y. Regulations on adaptive design clinical trials. Pharm Regul Aff Open Access. OMICS International; 2014;03.
12. Quinlan J, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J. 2006;40:437-44.
13. Gaydos B, Anderson KM, Berry D, Burnham N, Chuang-Stein C, Dudinak J, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J. 2009;43:539-56.
14. Thorlund K, Haggstrom J, Park JJ, Mills EJ. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. British Medical Journal Publishing Group. 2018;360:k698.
15. Park JJ, Thorlund K, Mills EJ. Critical concepts in adaptive clinical trials. Clin Epidemiol. Dove Press. 2018;10:343-51.
16. Chow S-C, Chang M. Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis. 2008;3:11.
17. Jaki T. Designing multi-arm multi-stage clinical studies. Developments in Statistical Evaluation of Clinical Trials. Springer; 2014. p. 51-69. Available from: http://link.springer.com/10.1007/978-3-642-55345-5-3.
18. Hatfield I, Allison A, Flight L, Julious SA, Dimairo M. Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials. BioMed Central. 2016;17:150.
19. Sato A, Shimura M, Gosho M. Practical characteristics of adaptive design in phase 2 and 3 clinical trials. J Clin Pharm Ther. 2018;43(2):170-80.
20. Lin M, Lee S, Zhen B, Scott J, Horne A, Solomon G, et al. CBER's experience with adaptive design clinical trials. Ther Innov Regul Sci. 2015;50:195-203.
21. Yang X, Thompson L, Chu J, Liu S, Lu H, Zhou J, et al. Adaptive design practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013. Ther Innov Regul Sci. SAGE Publications. 2016;50:710-7.
22. Morgan CC, Huyck S, Jenkins M, Chen L, Bedding A, Coffey CS, et al. Adaptive design: results of 2012 survey on perception and use. Ther Innov Regul Sci. 2014;48:473-81.
23. Bauer P, Einfalt J. Application of adaptive designs - a review. Biom J. 2006;48:493-506.
24. Curtin F, Heritier S. The role of adaptive trial designs in drug development. Expert Rev Clin Pharmacol. 2017;10(7):727-36.
25. Elsäßer A, Regnstrom J, Vetter T, Koenig F, Hemmings RJ, Greco M, et al. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials. 2014;15:383.
26. Dimairo M, Boote J, Julious SA, Nicholl JP, Todd S. Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials. Trials. BioMed Central Ltd. 2015;16:430.
27. Meurer WJ, Legocki L, Mawocha S, Frederiksen SM, Guetterman TC, Barsan W, et al. Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project. Trials. BioMed Central. 2016;17:373.
28. Dimairo M, Julious SA, Todd S, Nicholl JP, Boote J. Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials. Trials. BioMed Central Ltd. 2015;16:585.
29. Love SB, Brown S, Weir CJ, Harbron C, Yap C, Gaschler-Markefski B, et al. Embracing model-based designs for dose-finding trials. Br J Cancer. Nature Publishing Group. 2017;117:332-9.
30. Jaki T. Uptake of novel statistical methods for early-phase clinical studies in the UK public sector. Clin Trials. 2013;10:344-6.
31. Quinlan J, Gaydos B, Maca J, Krams M. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials. 2010;7:167-73.
32. Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, et al. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop. Clin Trials. 2012;9:671-80.
33. Dimairo M. The utility of adaptive designs in publicly funded confirmatory trials. 2016. http://etheses.whiterose.ac.uk/13981. Accessed 7 July 2017.
34. Stevely A, Dimairo M, Todd S, Julious SA, Nicholl J, Hind D, et al. An investigation of the shortcomings of the CONSORT 2010 statement for the reporting of group sequential randomised controlled trials: a methodological systematic review. PLoS One. 2015;10:e0141104.
35. Mistry P, Dunn JA, Marshall A. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. BMC Med Res Methodol. BMC Medical Research Methodology. 2017;17:108.
36. Stevely A, Dimairo M, Todd S, Julious SA, Nicholl J, Hind D, et al. An investigation of the shortcomings of the CONSORT 2010 Statement for the reporting of group sequential randomised controlled trials: a methodological systematic review. Shamji M, editors. PLoS One. Public Library of Science; 2015;10:e0141104.
37. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726-32.
38. Detry MA, Lewis RJ, Broglio KR, Connor JT, Berry SM, Berry DA. Standards for the design, conduct, and evaluation of adaptive randomized clinical trials. Washington: Patient-Centered Outcomes Research Institute; 2012. http://www.pcori.org/assets/Standards-for-the-Design-Conduct-and-Evaluation-of-Adaptive-Randomized-Clinical-Trials.pdf. Accessed 7 July 2017.
39. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. Public Library of Science. 2010;7:e1000217.
40. Dimairo M, Todd S, Julious S, Jaki T, Wason J, Hind D, et al. ACE Project Protocol Version 2.3: development of a CONSORT Extension for adaptive clinical trials [Internet]. EQUATOR Netw. 2016 [cited 2018 Jan 25]. Available from: http://www.equator-network.org/wp-content/uploads/2017/12/ACE-Project-Protocol-v2.3.pdf
41. Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review of barriers and opportunities. Trials. 2012;13:145.
42. The EQUATOR Network [Internet]. [cited 2016 Oct 10]. Available from: http://www.equator-network.org/reporting-guidelines/.
43. Dragalin V. Adaptive designs: terminology and classification. Drug Inf J. 2006;40:425-35.
44. Cook T, DeMets DL. Review of draft FDA adaptive design guidance. J Biopharm Stat. 2010;20:1132-42.
45. Chow S-C, Corey R. Benefits, challenges and obstacles of adaptive clinical trial designs. Orphanet J Rare Dis. 2011;6:79.
46. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development - an executive summary of the PhRMA Working Group. J Biopharm Stat. 2006;16:275-83 discussion 285-91, 293-8, 311-2.
47. Rosenberg MJ. The agile approach to adaptive research: optimizing efficiency in clinical development. 1st ed. Hoboken: John Wiley & Sons, Inc; 2010.
48. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthén B, et al. Adaptive designs for randomized trials in public health. Annu Rev Public Health. NIH Public Access. 2009;30:1-25.
49. Wang SJ, Hung HM, O'Neill R. Adaptive design clinical trials and trial logistics models in CNS drug development. Eur Neuropsychopharmacol. 2011;21(2):159-66.
50. Elman SA, Ware JH, Gottlieb AB, Merola JF. Adaptive clinical trial design: an overview and potential applications in dermatology. J Invest Dermatol. 2016;136:1325-9.
51. Porcher R, Lecocq B, Vray M, D'Andon A, Bassompierre F, Béhier J-M, et al. Adaptive methods: when and how should they be used in clinical trials? Therapie. 2011;66:319-26.
52. Maca J, Dragalin V, Gallo P. Adaptive clinical trials: overview of phase III designs and challenges. Ther Innov Regul Sci. 2014;48:31-40.
53. Bauer P, Brannath W. The advantages and disadvantages of adaptive designs for clinical trials. Drug Discov Today. 2004;9:351-7.
54. Coffey CS, Kairalla JA. Adaptive clinical trials: progress and challenges. Drugs R D. 2008;9:229-42.
55. Gallo P. Operational challenges in adaptive design implementation. Pharm Stat. John Wiley & Sons, Ltd. 2006;5:119-24.
56. Gaydos B, Anderson KM, Berry D, Burnham N, Chuang-Stein C, Dudinak J, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Ther Innov Regul Sci. 2009;43:539-56.
57. Phillips AJ, Keene ON. Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group. Pharm Stat. John Wiley & Sons, Ltd. 2006;5:61-6.
58. Gould AL. How practical are adaptive designs likely to be for confirmatory trials? Biom J. 2006;48:644-9.
59. Spencer K, Colvin K, Braunecker B, Brackman M, Ripley J, Hines P, et al. Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 study. J Diabetes Sci Technol. 2012;6:1296-304.
60. Koch A. Confirmatory clinical trials with an adaptive design. Biom J. 2006;48:574-85.
61. Chuang-Stein C, Beltangady M. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective. J Biopharm Stat. 2010;20:1143-9.
62. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasibility Stud. BioMed Central. 2016;2:64.
63. Kirkham JJ, Gorst S, Altman DG, Blazeby J, Clarke M, Devane D, et al. COS-STAR: a reporting guideline for studies developing core outcome sets (protocol). Trials. BioMed Central. 2015;16:373.
64. Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Doré C, et al. Guidelines for the content of statistical analysis plans in clinical trials. JAMA. American Medical Association. 2017;318:2337.
65. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
66. Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67:401-9.
67. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77-101.
68. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159.
69. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. Institute of Mathematical Statistics. 1979;7:1-26.
70. Bland M, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. Elsevier. 1986;327:307-10.
71. Akacha M, Bretz F, Ruberg S. Estimands in clinical trials - broadening the perspective. Stat Med. 2017;36:5-19.
72. Akacha M, Bretz F, Ohlssen D, Rosenkranz G, Schmidli H. Estimands and their role in clinical trials. Stat Biopharm Res. Taylor & Francis. 2017;9:268-71.
73. Phillips A, Abellan-Andres J, Soren A, Bretz F, Fletcher C, France L, et al. Estimands: discussion points from the PSI estimands and sensitivity expert group. Pharm Stat. 2017;16:6-11.
74. Extensions of the CONSORT Statement [Internet]. [cited 2018 May 21]. Available from: http://www.consort-statement.org/extensions.
75. Blanco D, Biggane AM, Cobo E. Are CONSORT checklists submitted by authors adequately reflecting what information is actually reported in published papers? Trials. BioMed Central. 2018;19:80.
76. Agha RA, Fowler AJ, Rajmohan S, Barai I, Orgill DP, Afifi R, et al. Preferred reporting of case series in surgery; the PROCESS guidelines. Int J Surg. 2016;36:319-23.
77. Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, Nikles J, Zucker DR, Kravitz R, Guyatt G, Altman DG, Moher D; CENT Group. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. J Clin Epidemiol. 2016;76:9-17. https://doi.org/10.1016/j.jclinepi.2015.05.004. Epub 2015 Aug 10. PubMed PMID: 26272792.
78. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Heal Med. SAGE Publications. 2013;2:38-43.
79. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Heal. Elsevier. 2013;16:231-50.
80. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. BMJ Publishing Group. 2016;355:i5239.
81. Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. PLoS Med. Public Library of Science. 2016;13:e1002056.
82. Bothwell LE, Avorn J, Khan NF, Kesselheim AS. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov. BMJ Open. British Medical Journal Publishing Group. 2018;8:e018320.
83. Lorch U, O'Kane M, Taubel J. Three steps to writing adaptive study protocols in the early phase clinical development of new medicines. BMC Med Res Methodol. 2014;14:1-9.
84. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. von Elm E, editor. PLoS Med. Public Library of Science; 2008;5:e20.
85. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371:281-3.